Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters











Database
Language
Publication year range
1.
Sci Rep ; 6: 35320, 2016 10 13.
Article in English | MEDLINE | ID: mdl-27734956

ABSTRACT

Normalization of altered glutamate neurotransmission through activation of the mGluR2 has emerged as a new approach to treat schizophrenia. These studies describe a potent brain penetrant mGluR2 positive allosteric modulator (PAM), SAR218645. The compound behaves as a selective PAM of mGluR2 in recombinant and native receptor expression systems, increasing the affinity of glutamate at mGluR2 as inferred by competition and GTPγ35S binding assays. SAR218645 augmented the mGluR2-mediated response to glutamate in a rat recombinant mGluR2 forced-coupled Ca2+ mobilization assay. SAR218645 potentiated mGluR2 agonist-induced contralateral turning. When SAR218645 was tested in models of the positive symptoms of schizophrenia, it reduced head twitch behavior induced by DOI, but it failed to inhibit conditioned avoidance and hyperactivity using pharmacological and transgenic models. Results from experiments in models of the cognitive symptoms associated with schizophrenia showed that SAR218645 improved MK-801-induced episodic memory deficits in rats and attenuated working memory impairment in NMDA Nr1neo-/- mice. The drug reversed disrupted latent inhibition and auditory-evoked potential in mice and rats, respectively, two endophenotypes of schizophrenia. This profile positions SAR218645 as a promising candidate for the treatment of cognitive symptoms of patients with schizophrenia, in particular those with abnormal attention and sensory gating abilities.


Subject(s)
Attention/drug effects , Cognition Disorders/drug therapy , Cognition/drug effects , Indans/pharmacology , Memory/drug effects , Oxazoles/pharmacology , Pyrimidines/pharmacology , Receptors, AMPA/chemistry , Schizophrenia/drug therapy , Allosteric Site , Amphetamines/pharmacology , Animals , Calcium/metabolism , Cerebral Cortex/metabolism , Cyclic AMP/metabolism , Dizocilpine Maleate/chemistry , Dizocilpine Maleate/pharmacology , Electroconvulsive Therapy , HEK293 Cells , Humans , Indans/therapeutic use , Male , Maze Learning , Memory, Short-Term/drug effects , Mice , Mice, Inbred C57BL , Mice, Transgenic , Oxazoles/therapeutic use , Phenotype , Pyrimidines/therapeutic use , Rats , Rats, Sprague-Dawley
2.
Psychopharmacology (Berl) ; 215(1): 149-63, 2011 May.
Article in English | MEDLINE | ID: mdl-21181124

ABSTRACT

RATIONALE: The psychotomimetic effects of cannabis are believed to be mediated via cannabinoid CB1 receptors. Furthermore, studies have implicated CB1 receptors in the pathophysiology of schizophrenia. OBJECTIVE: These studies investigated the effects of the CB1 receptor antagonist, AVE1625, in acute pharmacological and neurodevelopmental models of schizophrenia. AVE1625 was administered to rodents alone or as a co-treatment with clinically used antipsychotic drugs (APDs). METHODS: The antipsychotic potential of AVE1625 was tested using psychotomimetic-induced hyperactivity and latent inhibition (LI) deficit models. The procognitive profile was assessed using hole board, novel object recognition, auditory evoked potential, and LI techniques. In addition, the side-effect profile was established by measuring catalepsy, antipsychotic-induced weight gain, plasma levels of prolactin, and anxiogenic potential. RESULTS: AVE1625 (1, 3, and 10 mg/kg ip), reversed abnormally persistent LI induced by MK-801 or neonatal nitric oxide synthase inhibition in rodents, and improved both working and episodic memory. AVE1625 was not active in positive symptom models but importantly, it did not diminish the efficacy of APDs. It also decreased catalepsy and weight gain induced by APDs, suggesting that it may decrease APD-induced extrapyramidal side effects (EPS) and compliance. Unlike other CB1 antagonists, AVE1625 did not produce anxiogenic-like effects. CONCLUSIONS: These preclinical data suggest that AVE1625 may be useful to treat the cognitive deficits in schizophrenia and as a co-treatment with currently available antipsychotics. In addition, an improved side-effect profile was seen, with potential to ameliorate the EPS and weight gain issues with currently available treatments.


Subject(s)
Antipsychotic Agents/adverse effects , Antipsychotic Agents/therapeutic use , Cognition/drug effects , Hydrocarbons, Halogenated/therapeutic use , Receptor, Cannabinoid, CB1/antagonists & inhibitors , Schizophrenia/drug therapy , Sulfonamides/therapeutic use , Acoustic Stimulation , Amphetamine/pharmacology , Animals , Antipsychotic Agents/administration & dosage , Anxiety/chemically induced , Anxiety/prevention & control , Behavior, Animal/drug effects , Catalepsy/chemically induced , Catalepsy/prevention & control , Conditioning, Classical/drug effects , Disease Models, Animal , Drug Evaluation, Preclinical , Drug Therapy, Combination , Evoked Potentials, Auditory/drug effects , Hydrocarbons, Halogenated/administration & dosage , Hydrocarbons, Halogenated/adverse effects , Male , Mice , Mice, Inbred Strains , Rats , Rats, Sprague-Dawley , Schizophrenia/metabolism , Schizophrenia/physiopathology , Sulfonamides/administration & dosage , Sulfonamides/adverse effects , Weight Gain/drug effects
3.
Neuropsychopharmacology ; 34(7): 1753-63, 2009 Jun.
Article in English | MEDLINE | ID: mdl-19158670

ABSTRACT

Schizophrenia symptoms can be segregated into positive, negative and cognitive, which exhibit differential sensitivity to drug treatments. Accumulating evidence points to efficacy of alpha7 nicotinic receptor (nAChR) agonists for cognitive deficits in schizophrenia but their activity against positive symptoms is thought to be minimal. The present study examined potential pro-cognitive and antipsychotic activity of the novel selective alpha7 nAChR partial agonist SSR180711 using the latent inhibition (LI) model. LI is the reduced efficacy of a previously non-reinforced stimulus to gain behavioral control when paired with reinforcement, compared with a novel stimulus. Here, no-drug controls displayed LI if non-reinforced pre-exposure to a tone was followed by weak but not strong conditioning (2 vs 5 tone-shock pairings). MK801 (0.05 mg/kg, i.p.) -treated rats as well as rats neonatally treated with nitric oxide synthase inhibitor L-NoArg (10 mg/kg, s.c.) on postnatal days 4-5, persisted in displaying LI with strong conditioning, whereas amphetamine (1 mg/kg) -treated rats failed to show LI with weak conditioning. SSR180711 (0.3, 1, 3 mg/kg, i.p.) was able to alleviate abnormally persistent LI produced by acute MK801 and neonatal L-NoArg; these models are believed to model cognitive aspects of schizophrenia and activity here was consistent with previous findings with alpha7-nAChR agonists. In addition, unexpectedly, SSR180711 (1, 3 mg/kg, i.p.) potentiated LI with strong conditioning in no-drug controls and reversed amphetamine-induced LI disruption, two effects considered predictive of activity against positive symptoms of schizophrenia. These findings suggest that SSR180711 may be beneficial not only for the treatment of cognitive symptoms in schizophrenia, as reported multiple times previously, but also positive symptoms.


Subject(s)
Bridged Bicyclo Compounds, Heterocyclic/therapeutic use , Cognition Disorders/drug therapy , Neural Inhibition/drug effects , Nicotinic Agonists/therapeutic use , Schizophrenia/drug therapy , Acoustic Stimulation/adverse effects , Analysis of Variance , Animals , Animals, Newborn , Behavior, Animal/drug effects , Cognition Disorders/etiology , Conditioning, Psychological/drug effects , Disease Models, Animal , Dizocilpine Maleate/therapeutic use , Dose-Response Relationship, Drug , Drug Interactions , Enzyme Inhibitors/pharmacology , Male , Neuroprotective Agents/therapeutic use , Nitroarginine/pharmacology , Rats , Rats, Wistar , Receptors, Nicotinic , Reinforcement, Psychology , Schizophrenia/complications , alpha7 Nicotinic Acetylcholine Receptor
4.
Psychopharmacology (Berl) ; 202(1-3): 385-96, 2009 Jan.
Article in English | MEDLINE | ID: mdl-18709358

ABSTRACT

RATIONALE: SSR103800 and SSR504734 are novel glycine transport 1 (GlyT1) inhibitors with therapeutic potential for the treatment of schizophrenia. OBJECTIVE: The present studies investigated the effects of GlyT1 inhibitors in acute pharmacological and neurodevelopmental models of schizophrenia using latent inhibition in the rat; these latent inhibition (LI) models are believed to be predictive for treatments of positive, negative, and cognitive aspects of schizophrenia. MATERIALS AND METHODS: LI, the poorer conditioning to a previously irrelevant stimulus, was measured in a conditioned emotional response procedure in male rats. The effects of SSR103800 or SSR504734 (both at 1, 3, and 10 mg/kg, i.p.) were determined on amphetamine-induced disrupted LI, MK-801-induced abnormally persistent LI, and neurodevelopmentally induced abnormally persistent LI in adult animals that had been neonatally treated with a nitric oxide synthase inhibitor. RESULTS: SSR103800 (1 and 3 mg/kg) and SSR504734 (1 and 10 mg/kg) potentiated LI under conditions where LI was not present in nontreated controls and SSR103800 (1 mg/kg) reversed amphetamine-induced disrupted LI while not affecting LI on its own. Additionally, SSR103800 (1 and 3 mg/kg) and SSR504734 (3 and 10 mg/kg) reversed abnormally persistent LI induced by MK-801. In the neurodevelopmental model, SSR504734 (3 and 10 mg/kg) reverted the LI back to control (normal) levels. CONCLUSIONS: These preclinical data, from acute and neurodevelopmental models, suggest that GlyT1 inhibition may exhibit activity in the positive, negative, and cognitive symptom domains of schizophrenia.


Subject(s)
Aging/psychology , Antipsychotic Agents/pharmacology , Cognition/drug effects , Glycine Plasma Membrane Transport Proteins/antagonists & inhibitors , Reflex, Startle/drug effects , Schizophrenia/drug therapy , Schizophrenic Psychology , Amphetamine/antagonists & inhibitors , Amphetamine/toxicity , Animals , Animals, Newborn , Benzamides/pharmacology , Central Nervous System Stimulants/toxicity , Conditioning, Operant/drug effects , Dizocilpine Maleate/antagonists & inhibitors , Dizocilpine Maleate/toxicity , Dose-Response Relationship, Drug , Enzyme Inhibitors/pharmacology , Excitatory Amino Acid Antagonists/toxicity , Haloperidol/pharmacology , Male , Nitroarginine/pharmacology , Piperidines/pharmacology , Rats , Rats, Wistar
5.
Brain Res ; 1032(1-2): 44-9, 2005 Jan 25.
Article in English | MEDLINE | ID: mdl-15680940

ABSTRACT

The startle reflex is an unconditioned, quantifiable behavior used to study sensory modalities. We examined whether the acoustic startle reflex (ASR) was sensitive to lesions induced by focal cerebral ischemia. Sprague-Dawley rats were pre-screened for startle reflex responses 3-6 days prior to surgery and there were no differences in mean startle amplitude across groups. Animals were subjected to permanent middle cerebral artery occlusion (pMCAo) or a sham surgical procedure. Twenty-four hours later rats were evaluated for ASR prior to sacrifice. Infarct volumes were subsequently determined by quantitative image analysis of 2,3,5-triphenyltetrazolium chloride-stained brain sections. Infarct volumes of rats undergoing pMCAO ranged from 0 to 48%. Data were divided into three groups based upon percent infarction: mild (0-20%), moderate (21-35%), and severe (>35%). A within-subject analysis revealed a significant decrease in mean startle amplitude of only severely infarcted rats relative to their pre-surgery startle responses. Furthermore, the lesioned brain areas observed in these animals provide an anatomical basis for these results. Our findings demonstrate that ASR is affected in a model of stroke. Further work is needed to characterize this behavioral test and to determine whether it may have application as a surrogate endpoint for clinical stroke studies.


Subject(s)
Infarction, Middle Cerebral Artery/physiopathology , Reflex, Acoustic/physiology , Reflex, Startle/physiology , Acoustic Stimulation/methods , Analysis of Variance , Animals , Brain Infarction/pathology , Disease Models, Animal , Dose-Response Relationship, Radiation , Infarction, Middle Cerebral Artery/pathology , Male , Rats , Rats, Sprague-Dawley , Reflex, Acoustic/radiation effects , Reflex, Startle/radiation effects , Tetrazolium Salts
6.
Psychopharmacology (Berl) ; 179(1): 154-63, 2005 Apr.
Article in English | MEDLINE | ID: mdl-15672275

ABSTRACT

BACKGROUND: Positive alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) modulators enhance glutamate transmission via the AMPA receptor by altering the rate of desensitization; alone they have no intrinsic activity. They are the only class of compounds known that may pharmacologically separate AMPA subtypes. OBJECTIVE: This manuscript will review preclinical work on positive AMPA modulators, with clinical examples where relevant. RESULTS: The activity of these compounds appears to be determined by the AMPA receptor subunit composition. Studies have shown that splice variant and/or subunit combinations change the desensitization rate of this receptor. Also, these subunits are heterogeneously expressed across the central nervous system. Therefore, the functional outcome of different positive AMPA modulators could indeed be different. The origins of this pharmacological class come from hippocampal long-term potentiation studies, so quite naturally they were first studied in models of short- and long-term memory (e.g., delayed match to sample, maze performance). In general, these agents were procognitive. However, more recent work with different chemical classes has suggested additional therapeutic effects in models of schizophrenia (e.g., amphetamine locomotor activity), depression (e.g., forced swim test), neuroprotection (e.g., NMDA agonist lesions) and Parkinson's disease (e.g., 6-hydroxydopamine lesion). CONCLUSIONS: In conclusion, positive modulation of AMPA may offer numerous therapeutic avenues for central nervous system drug discovery.


Subject(s)
Alzheimer Disease/drug therapy , Receptors, AMPA/drug effects , Schizophrenia/drug therapy , Animals , Benzothiadiazines/pharmacology , Cognition/drug effects , Dioxoles/pharmacology , Humans , Long-Term Potentiation/drug effects , Memory/drug effects , Neuroprotective Agents/pharmacology , Piperidines/pharmacology , Protein Subunits , Receptors, AMPA/analysis , Receptors, AMPA/chemistry
7.
J Pharmacol Exp Ther ; 308(1): 214-20, 2004 Jan.
Article in English | MEDLINE | ID: mdl-14566007

ABSTRACT

Chronic relapsing/remitting experimental autoimmune encephalomyelitis (EAE) can be induced in 8-week-old female SJL/J(H-2) mice via inoculation with the p139-151 peptide of myelin proteolipid protein (PLP), Mycobacterium tuberculosis (MT), complete Freund's adjuvant (CFA), and Bordatella pertussis. EAE is a relevant preclinical model of MS that incorporates several aspects of the clinical disease. Chief among these are the inflammatory mediated neurological deficits. While the impact of localized spinal cord demyelination on neurotransmission has been modeled successfully, relatively little work has been done with spinal cord from animals with EAE. The goal of this study was to assess the utility of a grease-gap tissue bath methodology in the detection of transmission deficits in EAE spinal cord tissue. Spinal cords removed from EAE mice at different phases of the neurological deficit were assessed for their response to both lumbar and sacral application of one of several depolarizing agents (veratridine, potassium chloride [KCl], (+/-)-alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid [AMPA]). The main finding of this study is that transmission deficits were detected in EAE mice at the onset of the neurological deficits. They were sustained for a period of approximately 2 to 3 weeks post disease onset followed by a gradual recovery of group function. The other finding is that there is a decrease in the latency to achieve AMPA-mediated depolarization in sacral spinal cord that is independent of the magnitude of the depolarization response. These results suggest that this methodology can be utilized to assess sensory and motor deficits in spinal cord from EAE animals.


Subject(s)
Encephalomyelitis, Autoimmune, Experimental/physiopathology , Synaptic Transmission , Age Factors , Animals , Disease Models, Animal , Electrophysiology , Female , Mice , Potassium Chloride/pharmacology , Spinal Cord/physiopathology , Veratridine/pharmacology , alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid/pharmacology
8.
Schizophr Res ; 61(2-3): 195-205, 2003 Jun 01.
Article in English | MEDLINE | ID: mdl-12729871

ABSTRACT

In an effort to compare and contrast the mechanisms of action of typical and atypical antipsychotic drugs, [3H] 2-deoxyglucose metabolic mapping was employed following acute and chronic administration of haloperidol (1 mg/kg i.p. acute and 0.5 mg/kg i.p. chronic) and clozapine (20 mg/kg i.p., both acute and chronic). Optical density ratios (ODR) were measured in 62 brain structures. An overall decrease in ODR was observed in many of the regions analyzed. Acute haloperidol elicited significant decreases, particularly in the thalamus and hippocampus. Acute clozapine decreased glucose uptake in the caudate putamen, hippocampus, central gray, locus coreleus, and the thalamus. In both chronically treated haloperidol and clozapine animals, significant decreases in ODR were seen in the thalamus and hippocampal areas most dramatically, with other changes in the superior colliculus, retrospenial cortex, and the cerebellum. Clozapine caused significant effects in 32 nuclei acutely and only 19 nuclei chronically. Haloperidol caused significant effects in 23 nuclei acutely and 15 nuclei chronically. The pattern of change induced by haloperidol and clozapine were remarkably similar when considering their pharmacology is somewhat different. Both antipsychotics elicited fewer significant changes upon chronic administration.


Subject(s)
Antipsychotic Agents/pharmacology , Blood Glucose/metabolism , Brain/drug effects , Clozapine/pharmacology , Haloperidol/pharmacology , Tomography, Emission-Computed , Animals , Brain/diagnostic imaging , Brain Mapping , Deoxyglucose , Drug Administration Schedule , Energy Metabolism/drug effects , Long-Term Care , Male , Rats , Rats, Sprague-Dawley
SELECTION OF CITATIONS
SEARCH DETAIL